Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NASDAQ:AVTE NYSE:MBX NASDAQ:SBTX OTCMKTS:WIZP On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeAVTEAerovate Therapeutics$7.49+2.3%$8.64$56.35▼$105.00$217.10M0.9512,438 shs77,779 shsMBXMBX Biosciences$12.16+9.3%$12.19$4.81▼$27.50$406.44MN/A326,110 shs690,201 shsSBTXSilverback Therapeutics$17.50-0.8%$16.63$2.80▼$8.97$631.02M0.6337,931 shs715,589 shsWIZPMawson Infrastructure Group$0.42+2.6%$0.50$0.07▼$1.45$202.55M1.77141,517 shs261,238 shsElon Musk's Next MoveExplore Elon Musk’s boldest ventures yet—from AI and autonomy to space colonization—and find out how investors can ride the next wave of innovation.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceAVTEAerovate Therapeutics-6.51%+1.81%-29.95%-15.38%-87.48%MBXMBX Biosciences+9.25%-11.56%-8.43%+9.55%+1,215,999,900.00%SBTXSilverback Therapeutics-1.84%-0.17%+4.13%+31.32%+84.53%WIZPMawson Infrastructure Group0.00%-22.87%-17.08%-30.47%-53.72%Compare MarketRank™CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & ValuationAVTEAerovate TherapeuticsN/AN/AN/AN/AN/AN/AN/AN/AMBXMBX Biosciences2.7163 of 5 stars3.50.00.00.03.61.70.6SBTXSilverback TherapeuticsN/AN/AN/AN/AN/AN/AN/AN/AWIZPMawson Infrastructure GroupN/AN/AN/AN/AN/AN/AN/AN/ACompare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceAVTEAerovate Therapeutics 0.00N/AN/AN/AMBXMBX Biosciences 3.00Buy$37.63209.42% UpsideSBTXSilverback Therapeutics 0.00N/AN/AN/AWIZPMawson Infrastructure Group 0.00N/AN/AN/ACurrent Analyst Ratings BreakdownLatest WIZP, SBTX, MBX, and AVTE Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails8/5/2025MBXMBX BiosciencesMizuhoSubscribe to MarketBeat All Access for the recommendation accuracy ratingInitiated CoverageOutperform$38.007/16/2025MBXMBX BiosciencesOppenheimerSubscribe to MarketBeat All Access for the recommendation accuracy ratingInitiated CoverageOutperform$38.00(Data available from 8/9/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)Compare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookAVTEAerovate TherapeuticsN/AN/AN/AN/A$3.96 per shareN/AMBXMBX BiosciencesN/AN/AN/AN/AN/AN/ASBTXSilverback TherapeuticsN/AN/AN/AN/A$7.41 per shareN/AWIZPMawson Infrastructure GroupN/AN/AN/AN/A$0.03 per shareN/ACompare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateAVTEAerovate Therapeutics-$75.52M-$1.70N/AN/AN/AN/A-90.19%-77.47%8/11/2025 (Estimated)MBXMBX BiosciencesN/AN/A0.00N/AN/AN/AN/AN/AN/ASBTXSilverback Therapeutics-$89.48M-$2.42N/A∞N/AN/A-29.62%-28.20%N/AWIZPMawson Infrastructure Group-$3.45M-$0.33N/AN/AN/AN/AN/A-85.32%N/ALatest WIZP, SBTX, MBX, and AVTE EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails8/11/2025Q2 2025AVTEAerovate Therapeutics-$0.25N/AN/AN/AN/AN/ACompare DividendsCompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive GrowthAVTEAerovate TherapeuticsN/AN/AN/AN/AN/AMBXMBX BiosciencesN/AN/AN/AN/AN/ASBTXSilverback TherapeuticsN/AN/AN/AN/AN/AWIZPMawson Infrastructure GroupN/AN/AN/AN/AN/ACompare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioAVTEAerovate TherapeuticsN/A8.788.78MBXMBX BiosciencesN/AN/AN/ASBTXSilverback TherapeuticsN/A67.8767.87WIZPMawson Infrastructure GroupN/A1.131.13Compare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipAVTEAerovate TherapeuticsN/AMBXMBX BiosciencesN/ASBTXSilverback Therapeutics74.89%WIZPMawson Infrastructure GroupN/AInsider OwnershipCompanyInsider OwnershipAVTEAerovate Therapeutics24.90%MBXMBX Biosciences52.19%SBTXSilverback Therapeutics34.40%WIZPMawson Infrastructure GroupN/ACompare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableAVTEAerovate Therapeutics2028.99 million21.69 millionOptionableMBXMBX Biosciences3633.42 millionN/AN/ASBTXSilverback Therapeutics8336.06 million23.65 millionNot OptionableWIZPMawson Infrastructure Group2486.32 millionN/ANot OptionableWIZP, SBTX, MBX, and AVTE HeadlinesRecent News About These CompaniesMawson Infrastructure Group (OTCMKTS:WIZP) Stock Price Down 0% - Here's What HappenedAugust 1, 2025 | marketbeat.comMawson Infrastructure Group (OTCMKTS:WIZP) Stock Price Up 1.3% - Should You Buy?July 10, 2025 | marketbeat.comH.C. Wainwright Sticks to Their Hold Rating for Mawson Infrastructure Group (MIGI)April 2, 2025 | markets.businessinsider.comMawson Infrastructure releases 2025 company presentationJanuary 28, 2025 | markets.businessinsider.comMawson Infrastructure names William Regan as CFOJanuary 17, 2025 | markets.businessinsider.comMawson Infrastructure reports December revenue $5.26M, up 7% month/monthJanuary 14, 2025 | markets.businessinsider.comMawson Infrastructure executes new customer agreementJanuary 7, 2025 | markets.businessinsider.comMawson Infrastructure Group Inc (MIGI) Stock Trading RecapDecember 10, 2024 | bovnews.comBCreditors file Chapter 11 involuntary petition against Mawson Infrastructure, latter vows to 'vigorously defend' itselfDecember 6, 2024 | bizjournals.comWhy Is Mawson Infrastructure Group Inc (MIGI) Stock Lagging Behind -56.76% from Its 50-Day SMA?December 6, 2024 | bovnews.comBMawson Infrastructure reports August revenue $4.44M; digital colocation business up 166% Y/YSeptember 16, 2024 | seekingalpha.comMawson Infrastructure Group Inc (MIGI) Stock: More Strategic Than Meets the EyeAugust 24, 2024 | bovnews.comBMawson Infra Gr (NASDAQ:MIGI) Stock, Short Interest ReportAugust 14, 2024 | benzinga.comMawson Infrastructure Group adds new customer at Midland bitcoin facilityDecember 20, 2023 | bizjournals.comMawson announces agreement for half of Midland bitcoin facility capacityOctober 19, 2023 | bizjournals.comMawson Infrastructure reports BTC production of 69 in July, down 3% M/MAugust 24, 2023 | seekingalpha.comH.C. Wainwright Sticks to Its Buy Rating for Mawson Infrastructure Group (MIGI)August 24, 2023 | markets.businessinsider.comMawson Infrastructure Group Inc. Invites Submission of Indication of Interest for its BTC Hosting and HPC Co-location ServicesJuly 25, 2023 | technews.tmcnet.comTMawson Infrastructure Group Inc. Announces Monthly Operational Update for June 2023July 19, 2023 | businesswire.comMawson Infrastructure Group Inc. Announces Monthly Operational Update for May 2023June 14, 2023 | technews.tmcnet.comTMawson Infrastructure Group names new president, CEOMay 22, 2023 | bizjournals.comNew MarketBeat Followers Over TimeMedia Sentiment Over TimeWIZP, SBTX, MBX, and AVTE Company DescriptionsAerovate Therapeutics NASDAQ:AVTE$7.49 +0.17 (+2.32%) As of 08/8/2025Aerovate Therapeutics, Inc., a clinical-stage biopharmaceutical company, develops drugs that enhance the lives of patients with rare cardiopulmonary diseases in the United States. It focuses on advancing AV-101, a dry powder inhaled formulation of imatinib for the treatment of pulmonary arterial hypertension, which is in Phase 2b/Phase 3 trial. The company was incorporated in 2018 and is headquartered in Waltham, Massachusetts.MBX Biosciences NYSE:MBX$12.16 +1.03 (+9.25%) Closing price 08/8/2025 04:00 PM EasternExtended Trading$11.79 -0.37 (-3.03%) As of 08/8/2025 07:02 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.MBX Biosciences, Inc., a clinical-stage biopharmaceutical company, focuses on the discovery and development of precision peptide therapies for the treatment of endocrine and metabolic disorders. Its lead product candidate is MBX 2109, a parathyroid hormone peptide prodrug, which is in Phase 2 clinical trial designed as a potential long-acting hormone replacement therapy for the treatment of chronic hypoparathyroidism. The company is also developing MBX 1416, a long-acting glucagon-like peptide-1 (GLP-1) receptor antagonist that is in Phase 1 clinical trial designed as a potential therapy for post-bariatric hypoglycemia, a chronic complication of bariatric surgery. In addition, it is developing MBX 4291, a lead obesity product candidate, which is in investigational new drug-enabling studies designed as a long-acting and highly potent GLP-1 and glucose-dependent insulinotropic polypeptide receptor co-agonist prodrug for treating obesity and co-morbidities. The company was founded in 2018 and is based in Carmel, Indiana.Silverback Therapeutics NASDAQ:SBTX$17.50 -0.15 (-0.85%) As of 08/8/2025Silverback Therapeutics, Inc., a biopharmaceutical company, develops tissue-targeted therapeutics for the treatment of chronic viral infections, cancer, and other serious diseases. The company offers SBT8230 to treat chronic hepatitis B virus infection by eliciting an anti-viral immune response by targeting TLR8 activation to the liver. Silverback Therapeutics, Inc. was incorporated in 2016 and is headquartered in Seattle, Washington.Mawson Infrastructure Group OTCMKTS:WIZP$0.42 +0.01 (+2.56%) As of 08/1/2025Mawson Infrastructure Group, Inc. engages in the provision of digital asset infrastructure services. The company is headquartered in North Sydney, Australia. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30DroneEcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerFlying CarGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMade In AmericaMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSocial MediaSolarSpaceTechnologyTelecomToyUraniumUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas MarketBeat Week in Review – 08/04 - 08/08 Airbnb Beats Earnings, But the Growth Story Is Losing Altitude Dutch Bros Just Flipped the Script With a Massive Earnings Beat Amazon Takes an Equity Stake in IonQ—Any Upside Potential? D-Wave Delivers Growth Shock—Investors Eye Quantum Future Is Eli Lilly’s 14% Post-Earnings Slide a Buy-the-Dip Opportunity? Constellation Energy’s Earnings Beat Signals a New Era AppLovin’s Q2 Miss Spooks Market, But Wall Street Doubles Down Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
